Among advanced ESCC patients not selected based on PD-L1 expression, Sintilimab demonstrated the greatest OS benefit (HR = 0.70, 95% CI: 0.50-0.98). The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.